Edwards Lifesciences (EW) Stock Rating Reaffirmed at Canaccord Genuity; The $174.0 Target Indicates 30.17% Potential; Unipro Financial Services (UPRO)’s Sentiment Is 1

February 15, 2018 - By John Mackenzie

Among 28 analysts covering Edwards Lifesciences Corp (NYSE:EW), 22 have Buy rating, 1 Sell and 5 Hold. Therefore 79% are positive. Edwards Lifesciences Corp has $195 highest and $86 lowest target. $133.13’s average target is -0.40% below currents $133.67 stock price. Edwards Lifesciences Corp had 105 analyst reports since July 30, 2015 according to SRatingsIntel. On Thursday, July 27 the stock rating was maintained by Canaccord Genuity with “Buy”. On Monday, July 10 the stock rating was maintained by BMO Capital Markets with “Buy”. The firm has “Buy” rating given on Wednesday, October 11 by BMO Capital Markets. RBC Capital Markets maintained it with “Buy” rating and $12000 target in Tuesday, May 30 report. The company was maintained on Thursday, February 1 by BMO Capital Markets. JMP Securities reinitiated the shares of EW in report on Wednesday, January 6 with “Mkt Perform” rating. JMP Securities maintained the shares of EW in report on Friday, February 2 with “Market Outperform” rating. The company was initiated on Friday, January 8 by SunTrust. As per Wednesday, November 29, the company rating was maintained by Canaccord Genuity. The firm has “Buy” rating given on Wednesday, July 27 by BTIG Research.

The stock increased 1.87% or $2.64 during the last trading session, reaching $143.77. About 1.42M shares traded. ProShares UltraPro S&P500 (UPRO) has risen 59.77% since February 15, 2017 and is uptrending. It has outperformed by 43.07% the S&P500.

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. The company has market cap of $28.29 billion. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and their delivery systems for the nonsurgical replacement of heart valves. It has a 49.51 P/E ratio. The firm also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral replacement, and minimally invasive aortic heart valve system; and tissue heart valves and repair products, which are used to replace or repair a patient??s diseased or defective heart valve.

The stock increased 2.66% or $3.46 during the last trading session, reaching $133.67. About 613,133 shares traded. Edwards Lifesciences Corporation (NYSE:EW) has risen 15.41% since February 15, 2017 and is uptrending. It has underperformed by 1.29% the S&P500.

Edgestream Partners L.P. holds 1.22% of its portfolio in ProShares UltraPro S&P500 for 19,590 shares. Drw Securities Llc owns 28,247 shares or 1.01% of their US portfolio. Moreover, Portfolio Strategies Inc has 0.67% invested in the company for 3,458 shares. The Illinois-based Cmt Trading Llc has invested 0.47% in the stock. Sol Capital Management Co, a Maryland-based fund reported 6,000 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts